KBC Group
RCKT icon

KBC Group’s Rocket Pharmaceuticals RCKT Stock Holding History

KBC Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,475
Closed -$37K – 1797
2025
Q1 		$37K Hold
5,475
– – ﹤0.01% 1837
2024
Q4 		$69K Buy
5,475
+3,366
+160% +$50.7K ﹤0.01% 1741
2024
Q3 		$39K Hold
2,109
– – ﹤0.01% 1791
2024
Q2 		$45K Hold
2,109
– – ﹤0.01% 1679
2024
Q1 		$57K Buy
+2,109
New +$59.9K ﹤0.01% 1474

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

KBC Group's RCKT Position: Q2 2025 in Review

KBC Group sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 5,475 shares — an estimated $37K sold.

KBC Group first reported a position in RCKT in Q1 2024 and held it in 5 quarters. The position peaked at $69K in Q4 2024. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • KBC Group reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • KBC Group sold 5,475 Rocket Pharmaceuticals shares in Q2 2025, an estimated $37K.
  • KBC Group first reported a position in Rocket Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • KBC Group's Rocket Pharmaceuticals position peaked at $69K in Q4 2024.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on KBC Group's 13F filing for Q2 2025, filed 8 Aug 2025.